Company Description
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics.
It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics.
The company’s product candidate Delpacibart etedesiran is for the treatment of myotonic dystrophy type 1 and is currently in phase 3 trial.
Its other products in pipeline include Delpacibart zotadirsen for the treatment of duchenne muscular dystrophy, which is under phase 2 clinical development trial; and Delpacibart braxlosiran for the treatment of facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial.
The company is developing products for rare genetic cardiomyopathies for PRKAG2 syndrome and PLN cardiomyopathy.
Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2012 |
| IPO Date | Jun 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 391 |
| CEO | Sarah Boyce |
Contact Details
Address: 10578 Science Center Drive, Suite 125 San Diego, California 92121 United States | |
| Phone | 858 401 7900 |
| Website | aviditybiosciences.com |
Stock Details
| Ticker Symbol | RNA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001574111 |
| CUSIP Number | 05370A108 |
| ISIN Number | US05370A1088 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sarah Boyce | President, Chief Executive Officer and Director |
| Dr. Troy Edward Wilson J.D., Ph.D. | Co-Founder and Independent Chairman |
| Michael F. MacLean CPA | Chief Financial Officer |
| Dr. W. Michael F. Flanagan Ph.D. | Chief Scientific Officer |
| Teresa McCarthy | Chief Human Resources Officer |
| Eric B. Mosbrooker | Chief Commercial Officer |
| Prof. Mark E. Davis Ph.D. | Scientific Founder, Member of Scientific Advisory Board and Member of Board of Managers |
| Dr. Frank P. McCormick Ph.D. | Scientific Founder and Member of Scientific Advisory Board |
| Charles Calderaro III | Chief Technical Officer |
| John B. Moriarty Jr., ESQ., J.D. | Chief Legal Officer and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 16, 2016 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 1, 2016 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| May 8, 2015 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Apr 30, 2015 | 20-F | Annual and transition report of foreign private issuers |
| Mar 23, 2015 | 15-12B | Securities registration termination |
| Feb 17, 2015 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2015 | 6-K | Report of foreign issuer |
| Feb 12, 2015 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 11, 2015 | 25 | Filing |
| Feb 10, 2015 | 6-K | Report of foreign issuer |